At present, there are more and more infertile young men and women. The decision to give birth to boys and girls is up to men, and now the question of "whether to give birth or not" also falls on men. One book said that the number of male sperm should be 160 million. Now the male fertility is reduced because the number of sperm is less than 160 million and the quality is low. Of course, there are many factors, such as chemicals, radiation, and environmental pollution. But did you know that small laptops are also one of the killers of the next generation?
"Ct"
-
-
Disease
How effective is immunotherapy for gastric cancer? What other treatment options are available for gastric cancer?
Stomach cancer can cause abnormal symptoms in the digestive system, even vomiting blood and black stools, so it should be treated promptly after having stomach cancer
-
Disease
J Thorac Oncol: Survival Differences In Lung Cancer Patients By Gender And The Impact Of Prognostic Factors On Them
Research suggests that gender-related differences in lung cancer survival are largely determined by known prognostic factors, suggesting an opportunity to explore gender differences in treatment preference, choice and accessibility.
-
A study at Massachusetts General Hospital in the US demonstrated that Adagrasib alone and in combination with cetuximab delivered good results in patients with advanced colorectal cancer with KRAS G12C mutations, with 46% of subjects experiencing substantial tumour shrinkage and an efficacy rate of 100%.
-
Data from a study presented at the annual meeting of the European Society of Medical Oncology in 2022 showed that lenvatinib in combination with Pembrolizumab could give 100% efficacy in this group of patients.
-
Apparatus
New Drug Expected For Patients With Low HER2 Expression, FDA Grants Priority Review Status To Enhertu
The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.